Inari Medical Reports Third Quarter 2022 Financial Results

IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2022.

Third Quarter Revenue and Recent Business Highlights

  • Generated revenue of $96.2 million in the third quarter of 2022, up 32% over the same quarter last year.
  • Initiated full market release of two new products, Protrieve and InThrill. Both devices are priced outside of our per procedure pricing representing independent sources of revenue.
  • Presented three late breaking clinical trials at recent major medical conferences. Analyses of the full data sets of FLASH (800 PE patients) and CLOUT (500 DVT patients) confirm best in class safety and efficacy of FlowTriever and ClotTriever.
  • Ended the quarter with $319.2 million in cash, cash equivalents and short-term investments.

“Our aggressive investment in our growth drivers is paying off for our mission”, said Bill Hoffman, Chief Executive Officer of Inari Medical. “We launched two new products, our fifth and sixth of 2022, and presented three new data sets as late breaking clinical trials at major conferences. We continue to sense responsibility, not merely opportunity, for this work. I love so much that our team has committed to changing lives in the most beautiful ways.”

“We have committed to our patients and to big ideas, and I think you are seeing tangible results in the cadence of new product and data releases, as well as our overall performance”, continued Drew Hykes, Inari’s Chief Operating Officer and incoming CEO. “Our efforts continue to drive market expansion and uptake of our devices while further distancing Inari from both existing and future competition.”

Third Quarter 2022 Financial Results

Revenue was $96.2 million for the third quarter of 2022, compared to $72.9 million for the third quarter of 2021 and $92.7 million for the prior quarter. The increase over prior periods was driven primarily by continued U.S. commercial expansion, increased adoption of our procedures, and introduction of new products.

Gross profit was $85.1 million for the third quarter of 2022, compared to $65.9 million for the same period of 2021. Gross margin was 88.5% for the third quarter of 2022, compared to 90.3% for the same period in the prior year. The decrease in gross margin is primarily due to the addition of new products to our FlowTriever per procedure pricing model.

Operating expenses for the third quarter of 2022 were $94.9 million, compared to $68.6 million for the third quarter of 2021. The increase was mainly driven by personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.

Net loss was $10.2 million for the third quarter of 2022 and net loss per share was $0.19 on a weighted-average basic and diluted share count of 53.5 million, compared to a net loss of $2.8 million and a net loss per share of $0.06 on a weighted-average basic and diluted share count of 50 million, in the same period of the prior year.

Full-Year 2022 Revenue Guidance

For the full year 2022, we are increasing our revenue guidance from our previous range of $360 million to $370 million to a range of $373 million to $375 million.

Webcast and Conference Call Information

Inari Medical will host a conference call to discuss the third quarter 2022 financial results after market close on Wednesday, November 2, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers, using conference ID: 10172034. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2022 revenue, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:

ICR Westwicke
Caroline Corner
Phone +1-415-202-5678

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2022 2021 2022 2021
Revenue$96,204 $72,916 $275,700 $193,766
Cost of goods sold 11,064  7,040  31,378  16,477
Gross profit 85,140  65,876  244,322  177,289
Operating expenses       
Research and development 19,105  12,499  53,809  32,292
Selling, general and administrative 75,833  56,104  212,721  135,899
Total operating expenses 94,938  68,603  266,530  168,191
(Loss) income from operations (9,798)  (2,727)  (22,208)  9,098
Other income (expense)       
Interest income 618  27  882  130
Interest expense (74)  (73)  (220)  (220)
Other income (expense) (59)  30  169  (4)
Total other income (expenses) 485  (16)  831  (94)
(Loss) income before income taxes (9,313)  (2,743)  (21,377)  9,004
Provision for income taxes 840  61  2,092  271
Net (loss) income$(10,153) $(2,804) $(23,469) $8,733
Other comprehensive income (loss)       
Foreign currency translation adjustments (406)  (146)  (814)  (269)
Unrealized (loss) gain on available-for-sale debt securities 644  7  271  19
Total other comprehensive (loss) income 238  (139)  (543)  (250)
Comprehensive (loss) income$(9,915) $(2,943) $(24,012) $8,483
Net (loss) income per share       
Basic$(0.19) $(0.06) $(0.45) $0.18
Diluted$(0.19) $(0.06) $(0.45) $0.16
Weighted average common shares used to compute net
      (loss) income per share
Basic 53,491,625  50,001,996  52,552,662  49,664,037
Diluted 53,491,625  50,001,996  52,552,662  55,511,061

Condensed Consolidated Balance Sheets
(in thousands, except share data)
 September 30,
 December 31,
Current assets   
Cash and cash equivalents$83,528 $92,752
Short-term investments in debt securities 235,705  83,348
Accounts receivable, net 54,059  42,351
Inventories, net 29,670  21,053
Prepaid expenses and other current assets 7,609  5,694
Total current assets 410,571  245,198
Property and equipment, net 21,191  16,471
Operating lease right-of-use assets 49,951  44,909
Deposits and other assets 6,106  981
Long-term investments in debt securities   3,983
Total assets$487,819 $311,542
Liabilities and Stockholders' Equity   
Current liabilities   
Accounts payable$6,035 $6,541
Payroll-related accruals 28,052  24,433
Accrued expenses and other current liabilities 7,668  10,737
Operating lease liabilities, current portion 588  802
Total current liabilities 42,343  42,513
Operating lease liabilities, noncurrent portion 30,377  28,404
Other long-term liability   1,416
Total liabilities 72,720  72,333
Commitments and contingencies    
Stockholders' equity   
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares    issued and outstanding as of September 30, 2022 and December 31, 2021   
Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 53,595,277 and 50,313,452 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 53  50
Additional paid in capital 457,043  257,144
Accumulated other comprehensive loss (945)  (402)
Accumulated deficit (41,052)  (17,583)
Total stockholders' equity 415,099  239,209
Total liabilities and stockholders' equity$487,819 $311,542


Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.